Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 25, 2022

BUY
$194.69 - $268.46 $4.1 Million - $5.66 Million
21,074 New
21,074 $5.63 Million
Q3 2020

Oct 29, 2020

SELL
$264.77 - $305.71 $5.61 Million - $6.48 Million
-21,186 Closed
0 $0
Q2 2020

Jul 27, 2020

SELL
$258.66 - $342.55 $5.97 Million - $7.91 Million
-23,086 Reduced 52.15%
21,186 $5.68 Million
Q1 2020

Apr 14, 2020

SELL
$268.85 - $341.04 $1.58 Million - $2 Million
-5,861 Reduced 11.69%
44,272 $14 Million
Q4 2019

Jan 14, 2020

SELL
$220.06 - $304.07 $7.34 Million - $10.1 Million
-33,363 Reduced 39.96%
50,133 $14.9 Million
Q3 2019

Oct 10, 2019

BUY
$217.44 - $243.88 $833,882 - $935,279
3,835 Added 4.81%
83,496 $19.4 Million
Q2 2019

Jul 24, 2019

BUY
$219.29 - $241.72 $3.93 Million - $4.33 Million
17,901 Added 28.98%
79,661 $18.6 Million
Q1 2019

May 15, 2019

BUY
$216.71 - $338.96 $5.3 Million - $8.29 Million
24,461 Added 65.58%
61,760 $14.6 Million
Q4 2018

Feb 12, 2019

SELL
$278.5 - $352.75 $3.25 Million - $4.12 Million
-11,668 Reduced 23.83%
37,299 $11.2 Million
Q3 2018

Nov 09, 2018

BUY
$293.51 - $383.83 $8.58 Million - $11.2 Million
29,244 Added 148.27%
48,967 $17.3 Million
Q2 2018

Aug 08, 2018

BUY
$257.52 - $306.91 $102,492 - $122,150
398 Added 2.06%
19,723 $5.73 Million
Q1 2018

May 10, 2018

SELL
$260.13 - $367.91 $1.44 Million - $2.03 Million
-5,522 Reduced 22.22%
19,325 $5.29 Million
Q4 2017

Feb 08, 2018

SELL
$307.64 - $344.58 $15.1 Million - $16.9 Million
-49,143 Reduced 66.42%
24,847 $7.92 Million
Q3 2017

Oct 31, 2017

BUY
$281.15 - $329.69 $16.8 Million - $19.7 Million
59,651 Added 416.01%
73,990 $23.2 Million
Q2 2017

Aug 09, 2017

BUY
N/A
14,339
14,339 $3.89 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Artemis Investment Management LLP Portfolio

Follow Artemis Investment Management LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artemis Investment Management LLP, based on Form 13F filings with the SEC.

News

Stay updated on Artemis Investment Management LLP with notifications on news.